Cediranib plus olaparib significantly increases PFS in recurrent ovarian cancer

Bookmark and Share
Published: 31 May 2014
Views: 3178
Dr Joyce Liu - Dana-Farber Cancer Institute, Boston, USA

At a press conference at ASCO 2014, Dr Liu presents her work regarding a new immunotherapy drug combo, cediranib plus olaparib, which has been shown to significantly increase progression-free survival in recurrent ovarian cancer.

Read the article for more.